Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patients’ baseline demographics and characteristics

From: Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

  All IFX TCZ ABT p Valuea
Number of patients 209 140 38 31
Female sex, n (%) 172 (82.3 %) 113 (80.7 %) 34 (89.5 %) 25 (80.6 %) 0.46626
Age, yr, median (IQR) 59.0 (47.0–66.0) 57.5 (46.0–64.3) 56.0 (44.8–64.0) 67.0 (62.0–74.0) 0.00003
Disease duration, yr, median (IQR) 3.3 (1.1–10.5) 3.3 (1.1–10.3) 4.2 (1.5–9.4) 2.4 (0.5–14.5) 0.86013
Concomitant drug use
 Steroid use, n (%) 80 (38.3 %) 56 (40.0 %) 14 (36.8 %) 10 (32.3 %) 0.75247
 Steroid dose, mg/day, median (IQR) 0 (0–5.0) 0 (0–5.0) 0 (0–3.0) 0 (0–2.5) 0.34861
 MTX dose, mg/week, median (IQR) 8.0 (8.0–8.0) 8.0 (8.0–10.0) 8.0 (6.0–8.0) 8.0 (6.0–8.0) 0.00271
 csDMARD useb (except MTX), n (%) 29 (13.9 %) 20 (14.3 %) 5 (13.2 %) 4 (12.9 %) 1.00000
Serological markers
 RF positivity, n (%) 154 (74.8 %)c 103 (74.1 %)d 28 (73.7 %) 23 (79.3 %)e 0.88544
 RF titer, median (IQR) 55 (15–115)c 53 (14–115)d 54 (17–115) 77 (22–106)e 0.94307
 ACPA positivity, n (%) 85 (85.9 %)f 51 (85.0 %)g 13 (100 %)h 21 (80.8 %)i 0.31205
 ACPA titer, median (IQR) 85.6 (12.8–100)f 100 (13.3–100)g 83 (42.9–100)h 62.1 (9.8–100)i 0.89773
TJC28, median (IQR) 6.0 (2.0–8.0) 6.0 (2.0–8.3) 6.0 (3.0–8.8) 6.0 (3.0–8.0) 0.68798
SJC28, median (IQR) 6.0 (3.0–11.0) 7.0 (3.8–11.0) 6.0 (4.0–8.0) 5.0 (3.0–8.0) 0.46376
PtGA, mm, median (IQR) 53 (28–72) 52 (27–72) 52 (31–67) 63 (41–73) 0.34811
PhGA, mm, median (IQR) 43 (30–60) 43 (29–63) 43 (33–60) 45 (31–56) 0.91700
CRP, mg/dl, median (IQR) 0.9 (0.4–2.4) 1.0 (0.4–2.6) 0.6 (0.2–2.0) 0.8 (0.4–2.0) 0.19092
ESR, mm/h, median (IQR) 42 (25–69) 45 (28–69) 37 (22–60) 37 (23–74) 0.27517
DAS28-ESR, median (IQR) 5.3 (4.4–6.1) 5.3 (4.4–6.2) 5.1 (4.5–5.8) 5.5 (4.7–6.1) 0.65899
SDAI score, median (IQR) 22.5 (16.2–31.3) 23.2 (15.6–32.2) 22.1 (16.8–28.5) 23.3 (16.8–31.5) 0.96973
CDAI score, median (IQR) 21.7 (14.9–28.9) 21.9 (14.6–29.6) 20.6 (16.4–26.0) 22.8 (15.1–28.5) 0.99430
  1. Abbreviations: IFX infliximab, TCZ tocilizumab, ABT abatacept, IQR interquartile range, MTX methotrexate, csDMARD conventional synthetic disease-modifying antirheumatic drug, RF rheumatoid factor, ACPA anticyclic citrullinated peptide antibodies, TJC28 28 tender joint count, SJC28 28 swollen joint count, PtGA patient global assessment, PhGA physician global assessment, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score in 28 joints, SDAI simplified disease activity index, CDAI clinical disease activity index
  2. aKruskal-Wallis test was used for numerical variables to evaluate the differences between the three drug groups. For categorical variables, Fisher’s exact test was used. p < 0.05 was considered statistically significant
  3. bIncluding salazosulfapyridine, bucillamine, tacrolimus, d-penicillamine, actarit, and azathioprine
  4. cAvailable for 206 of 209
  5. dAvailable for 139 of 140
  6. eAvailable for 29 of 31
  7. fAvailable for 99 of 209
  8. gAvailable for 60 of 140
  9. hAvailable for 13 of 38
  10. iAvailable for 26 of 31